Literature DB >> 11313931

Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity.

M Kasten1, A Giordano.   

Abstract

Cdk10 is a Cdc2-related kinase that may play a role in regulating the G2/M phase of the cell cycle. However little is known about the proteins that interact with this putative kinase and contribute to its function in the cell. We report in this study that Cdk10 interacts with the N-terminus of the Ets2 transcription factor, which contains the highly conserved Pointed domain and transactivation domain. The Pointed domain has been implicated in protein-protein interactions and we find that Ets2 requires an intact Pointed domain to bind Cdk10. The Pointed domain of Ets1 is highly similar to Ets2, however Cdk10 does not recognize Ets1 in a two-hybrid assay thereby demonstrating significant binding specificity on the part of Cdk10. We find that Cdk10 binds full length Ets2 in vitro and in vivo and inhibits Ets2 transactivation in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313931     DOI: 10.1038/sj.onc.1204295

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  Sp100 interacts with ETS-1 and stimulates its transcriptional activity.

Authors:  Christine Wasylyk; Sophie E Schlumberger; Paola Criqui-Filipe; Bohdan Wasylyk
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

Review 2.  Functional evolution of cyclin-dependent kinases.

Authors:  John H Doonan; Georgios Kitsios
Journal:  Mol Biotechnol       Date:  2009-01-15       Impact factor: 2.695

3.  miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M.

Authors:  Jianhua Yu; Weiguang Zhang; Baochun Lu; Hongwei Qian; Haijun Tang; Zhiyang Zhu; Xinggui Yuan; Peitu Ren
Journal:  Oncol Lett       Date:  2017-12-28       Impact factor: 2.967

4.  Regulation of hormonal therapy resistance by cell cycle machinery.

Authors:  Binoj Chandrasekharan Nair; Ratna K Vadlamudi
Journal:  Gene Ther Mol Biol       Date:  2008-01-01

5.  Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment.

Authors:  Charles E Foulds; Mary L Nelson; Adam G Blaszczak; Barbara J Graves
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 6.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

7.  CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.

Authors:  Vincent J Guen; Carly Gamble; Marc Flajolet; Sheila Unger; Aurélie Thollet; Yoan Ferandin; Andrea Superti-Furga; Pascale A Cohen; Laurent Meijer; Pierre Colas
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

8.  Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.

Authors:  Maike Zimmermann; Aruni P S Arachchige-Don; Michaela S Donaldson; Tommaso Patriarchi; Mary C Horne
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

Review 9.  Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents.

Authors:  A E Leitch; C Haslett; A G Rossi
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

Review 10.  Review of Ets1 structure, function, and roles in immunity.

Authors:  Lee Ann Garrett-Sinha
Journal:  Cell Mol Life Sci       Date:  2013-01-05       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.